ProsTIC Theranostics

Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET scan and then a similar radioactive molecule that kills cancer cells. The ProsTIC program has three aims: 1. Accelerate clinical trial research: Expand the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high-impact need that are not currently being addressed. 2. Education and Leadership: Establish a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this new technology. 3. Discovery research: Further investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation. Email: prostic@petermac.org